Loading...
•
Sep 30, 2023
Reneo Pharmaceuticals Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023.
Key Takeaways
Reneo Pharmaceuticals reported a net loss of $19.2 million, or $0.57 per share, for the third quarter of 2023. The company had $125.6 million in cash, cash equivalents, and short-term investments as of September 30, 2023. Topline data results from the pivotal STRIDE study are expected in December 2023.
Completed last patient last visit in the pivotal STRIDE study; topline results expected in December 2023
Enrolled 88% of eligible STRIDE study patients in the STRIDE AHEAD open-label extension study; 65 patients treated beyond 52-weeks
Dosed the first patient with PMM due to a nuclear DNA (nDNA) defect in the STRIDE AHEAD open-label extension study
Repurchased 576,443 shares of common stock for approximately $4.4 million on October 30, 2023; all repurchased shares were retired
Forward Guidance
The company anticipates sharing topline results of the pivotal STRIDE study in December.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...